Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alice Long

Showing results (51-60 of 90) with videos related to

Pageof 9
Sort By:
The Journal of Clinical Investigation|August 13, 2024
Teplizumab induces persistent changes in the antigen-specific repertoire in individuals at risk for type 1 diabetesAna Lledó-Delgado, Paula Preston-Hurlburt, Sophia Currie, et al.
Cytometry. Part a : the Journal of the International Society for Analytical Cytology|December 30, 2021
A simple strategy for sample annotation error detection in cytometry datasetsMegan E Smithmyer, Alice E Wiedeman, David A G Skibinski, et al.
Frontiers in Immunology|July 1, 2025
Transcriptional fingerprinting of regulatory T cells: ensuring quality in cell therapy applicationsZhang Cheng, Li-Jie Wang, Yuchi Honaker, et al.
Diabetes|March 22, 2019
Dynamic Immune Phenotypes of B and T Helper Cells Mark Distinct Stages of T1D ProgressionTania Habib, S Alice Long, Peter L Samuels, et al.
Diabetologia|October 2, 2023
A first-in-human, open-label Phase 1b and a randomised, double-blind Phase 2a clinical trial in recent-onset type 1 diabetes with AG019 as monotherapy and in combination with teplizumabChantal Mathieu, Alice Wiedeman, Karen Cerosaletti, et al.
Science Translational Medicine|September 16, 2016
Enhanced T cell responses to IL-6 in type 1 diabetes are associated with early clinical disease and increased IL-6 receptor expressionChristian Hundhausen, Alena Roth, Elizabeth Whalen, et al.
Diabetes|October 24, 2024
Emerging Concepts and Success Stories in Type 1 Diabetes Research: A Road Map for a Bright FutureRoberto Mallone, Emily Sims, Peter Achenbach, et al.
The Journal of Clinical Investigation|September 30, 2025
Neutrophil-enriched gene signature correlates with teplizumab therapy resistance in different stages of type 1 diabetesGabriele Sassi, Pierre Lemaitre, Laia Fernández Calvo, et al.
Diabetologia|December 21, 2018
Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosisAna Luisa Perdigoto, Paula Preston-Hurlburt, Pamela Clark, et al.
Journal of Autoimmunity|January 31, 2015
Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patientsMichelle Rosenzwajg, Guillaume Churlaud, Roberto Mallone, et al.
Pageof 9

Showing results (51-60 of 90) with videos related to

Sort By:
Pageof 9
The Journal of Clinical Investigation|August 13, 2024
Teplizumab induces persistent changes in the antigen-specific repertoire in individuals at risk for type 1 diabetesAna Lledó-Delgado, Paula Preston-Hurlburt, Sophia Currie, et al.
Cytometry. Part a : the Journal of the International Society for Analytical Cytology|December 30, 2021
A simple strategy for sample annotation error detection in cytometry datasetsMegan E Smithmyer, Alice E Wiedeman, David A G Skibinski, et al.
Frontiers in Immunology|July 1, 2025
Transcriptional fingerprinting of regulatory T cells: ensuring quality in cell therapy applicationsZhang Cheng, Li-Jie Wang, Yuchi Honaker, et al.
Diabetes|March 22, 2019
Dynamic Immune Phenotypes of B and T Helper Cells Mark Distinct Stages of T1D ProgressionTania Habib, S Alice Long, Peter L Samuels, et al.
Diabetologia|October 2, 2023
A first-in-human, open-label Phase 1b and a randomised, double-blind Phase 2a clinical trial in recent-onset type 1 diabetes with AG019 as monotherapy and in combination with teplizumabChantal Mathieu, Alice Wiedeman, Karen Cerosaletti, et al.
Science Translational Medicine|September 16, 2016
Enhanced T cell responses to IL-6 in type 1 diabetes are associated with early clinical disease and increased IL-6 receptor expressionChristian Hundhausen, Alena Roth, Elizabeth Whalen, et al.
Diabetes|October 24, 2024
Emerging Concepts and Success Stories in Type 1 Diabetes Research: A Road Map for a Bright FutureRoberto Mallone, Emily Sims, Peter Achenbach, et al.
The Journal of Clinical Investigation|September 30, 2025
Neutrophil-enriched gene signature correlates with teplizumab therapy resistance in different stages of type 1 diabetesGabriele Sassi, Pierre Lemaitre, Laia Fernández Calvo, et al.
Diabetologia|December 21, 2018
Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosisAna Luisa Perdigoto, Paula Preston-Hurlburt, Pamela Clark, et al.
Journal of Autoimmunity|January 31, 2015
Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patientsMichelle Rosenzwajg, Guillaume Churlaud, Roberto Mallone, et al.
Pageof 9